Previous 10 |
home / stock / abscf / abscf news
Masitinib, under development from AB Science (ABSCF) for metastatic castrate-resistant prostate cancer (mCRPC), met its primary endpoint in a phase 2b/3 study.In the study, patients were randomized to masitinib and docetaxel vs docetaxel alone with the progression-free survival as the primary...
AB Science (ABSCF) has licensed masitinib, a drug it is currently investigating for multiple neurological, inflammatory and cancer indications, to the University of Chicago to research the candidate as a potential COVID-19 treatment.University of Chicago researchers previously found that masi...
Eli Lilly recently released generally positive results for its anti-amyloid drug donanemab. Drugs that directly or indirectly target amyloid oligomers which activate various receptors appear to have little effect on non-ApoE4 carriers and only a modest effect on ApoE4 carriers. Ta...
Masitinib appeared to delay the progression to severe Alzheimer's disease during a 24 week time frame. Masitinib acts as an inhibitor of tyrosine kinases which may help slow cognitive decline in mild to moderate Alzheimer's disease. The magnitude of this effect likely shrinks over...
With a rise of +5.7% today, the shares of AB Science (ABSCF) are on a tear after the company announced positive data for its Phase 2B/3 study for oral masitinib in mild and moderate Alzheimer’s disease.The international, randomized, placebo-controlled stud...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
News, Short Squeeze, Breakout and More Instantly...
Ab Science Paris Ord Company Name:
ABSCF Stock Symbol:
OTCMKTS Market:
PRESS RELEASE AB SCIENCE REPORTS POSTIVE RESULTS OF ITS PHASE 2 STUDY EVALUATING MASITINIB IN COVID-19 Paris, 8 July 2024, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announces the results of a Phase 2 study evaluating masitinib in COVID-19. This rando...
PRESS RELEASE SUMMARY OF THE WEBCAST HELD ON MAY 30, 2024, PROVIDING AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, May 31, 2024, 4.30pm CET AB Science SA (Euronext - FR0010557264...
PRESS RELEASE AB SCIENCE PROVIDES AN UPDATE ON THE APPLICATION FOR CONDITIONAL MARKETING AUTHORISATION OF MASITINIB IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Paris, 29 May, 2024, 6pm CET AB Science SA (Euronext - FR0010557264 - AB) today announces that the Commit...